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Abstract
Acne vulgaris is a common inflammatory disease. Among patients with darker skin phototypes (Fitzpatrick III–VI), the
inflammatory processes of acne stimulate excess melanogenesis and abnormal melanin deposition, leading to pigmentary
sequelae known as post-inflammatory hyperpigmentation and post-inflammatory erythema in all skin tones, although postinflammatory hyperpigmentation is more common in darker skin and post-inflammatory erythema in lighter skin. These
pigmentary alterations can be long lasting and are often more distressing to patients than the active acne lesions. This article
discusses what is known about acne-related pigmentation, much of which is extrapolated from general study of nonspecific
pigment deposition. Because dyspigmentation poses both a significant clinical concern to patients and a therapeutic challenge to clinicians, we formed a working group consisting of pigmentary experts with the aim of increasing awareness and
education of acne-related pigmentary sequelae.

Key Points

1 Introduction

Pigmentary deposition is an important problem for acne
patients, particularly those with darker skin.

Acne is one of the most common dermatologic diseases
across all racial and ethnic backgrounds. For many patients,
it is often accompanied by pigmentary sequelae, including post-inflammatory hyperpigmentation (PIH) and postinflammatory erythema (PIE) [1–4]. Acne-associated PIH
occurs most commonly in individuals with darker skin
(Fitzpatrick skin phototypes IV–VI), with reported ranges
from 45.5 to 87.2%, and both acne and associated dyschromias rank among the chief complaints that bring patients

Preventing the development of PIH during the inflammatory acne phase is a key strategy.
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Fig. 1  Clinical photos
illustrating color differences
between post-inflammatory
hyperpigmentation (PIH) and
post-inflammatory erythema
(PIE). Courtesy of Galderma
Laboratories, LP

with skin of color to dermatology offices [5–11]. Although
there are no standard criteria distinguishing PIH from PIE,
many clinicians associate PIH with brown-to-violaceous
tones and PIE with pink-to-red tones (Fig. 1) [5, 12, 13]. In
addition, some clinicians are more likely to use the term PIE
in cases where there are still active acne lesions intermingled with skin dyschromia [5]. As noted by Goh et al., PIH
and erythema are often present together, which can pose a
challenge when diagnosing and communicating about acnerelated PIH [6].
For many acne sufferers with darker skin tones, PIH is
at least as concerning as the acne lesions themselves and in
many cases is considered even more troublesome than the
acne [14]. Acne-associated PIH has been shown to affect
quality of life; in a cross-sectional survey of 200 patients,
acne-related PIH was associated with diminished social life,
avoidance of public facilities, poor body image/self-esteem,
and a perception of more severe disease [5, 15, 16]. Recent
studies have indicated that acne-related pigmentation is frequently long lasting [5, 16]. In a Southeast Asian population, 58.2% of patients reported PIH to have been present for
more than 1 year and 22.3% reported dyschromia persisting
for ≥ 5 years [5]; similarly, 52.6% of patients with acne in
the Middle East reported that PIH had been present for at
least 1 year [16]. Modifiable risk factors for acne-related
pigmentary problems have been identified, and include
delays in seeking treatment for acne and excoriation of acne
lesions [5, 8, 17, 18]. However, in patients with acne and in
comparison to PIH as a result of other causes, the literature
regarding acne-associated PIH remains sparse particularly
in regard to the condition’s pathogenesis and management.
This article summarizes current knowledge and identifies
areas of future study that could be clinically beneficial.

2 Methods of Literature Review
A review and analysis of the medical literature were conducted using the National Library of Medicine’s PubMed
database. The search was initiated with the string: (“PIH”)
or (“hyperpigmentation”) or (“postinflammatory”) or (“postinflammatory”) or (“postinflammatory hyperpigmentation”)
or (“post-inflammatory hyperpigmentation”) and “acne;”
this yielded a total of 538 studies (Fig. 2) and included
publications from 1985 to 2021. These were individually
reviewed for relevance; publications with PIH as a complication or a side effect and those focused on acne scars or melasma were eliminated. A total of 162 publications remained
that were judged directly relevant to the topic of acne and
PIH; the PubMed filter for clinical trials was applied, resulting in 22 publications. The 22 clinical trials were further
evaluated to determine the population studied, resulting
in six publications with African American/Black subjects,
five with Asian subjects, one with a Hispanic population,
and ten with mixed populations. The same search logic was
applied for the terms in the tabular portion of the figure;
each search result was manually reviewed for relevance to
this publication and any duplications between search results
were removed.
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Fig. 2  Flow chart showing the literature search query strategy. PIH post-inflammatory hyperpigmentation
Fig. 3  Post-inflammatory
hyperpigmentation. Normal (A)
and post-inflammatory hyperpigmentation involved (B) skin
sections (10× magnification,
hematoxylin and eosin staining).
Photographs courtesy of Pearl
Grimes, unpublished histological study of post-inflammatory
hyperpigmentation

3 Results: Current Understanding
of the Pathogenesis of Acne‑Associated
PIH
3.1 Acne and Inflammation
In acne-related PIH, it is believed that acne-associated
inflammation stimulates melanogenesis and resultant pigment deposition (Fig. 3) [19]. Over the past decade, increasing evidence has pointed to a role for inflammation at all
stages of acne, even at the subclinical level prior to formation of comedones [20, 21]. A lymphocytic perivascular
infiltrate has been identified in acne lesions just 6–72 h old,
including lesions identified as microcomedones, evidence
that inflammatory events occur very early in the development of acne lesions [22]. A study of uninvolved skin has
suggested that inflammatory events may also occur before

initial hyperproliferative changes [21]. The exact signaling pathways of acne-related inflammation are not yet
completely understood; however, potential early sources
of inflammation include sebum dynamics and the innate
immune response to Cutibacterium acnes [20].

3.2 Acne, Inflammation, and Pigmentation
As noted in Sect. 3.1, acne-associated inflammation has a
marked impact on pigment-producing melanocytes; thus,
it seems reasonable that reducing inflammation at the cellular level can reduce the likelihood of pigment deposition
[19]. The inflammatory process of acne stimulates melanocytes to over-produce or irregularly disperse melanin [19,
23]. While the exact pathogenesis of acne-related PIH is
incompletely understood, it is thought that the release of
arachidonic acid in response to epidermal inflammatory
events leads to oxidation of prostaglandins, leukotrienes,

N. Elbuluk et al.

and other molecules that stimulate melanocyte activity
[24]. As more melanin is synthesized, more pigment is distributed to keratinocytes [24, 25]. Generally, it is believed
that the intensity of pigmentary response correlates with
the degree of inflammation and long-term and/or relapsing
inflammation [26]. However, to date, there are no validated outcome measures or imaging techniques available
for clinical or research use.
There are few data to inform clinicians about whether
acne-related PIH differs from PIH associated with other
causes in any physiologic aspects. In 2015, Isedeh and colleagues validated an in vivo model for PIH using exposure
to 35% trichloroacetic acid to induce pigmentation [27].
An 8-week pilot study comparing the trichloroacetic acidtreated sites with PIH associated with acne lesions showed
that while the initial phases of inflammation were different
between the two types of pigmentation, similar clinical
evaluations were made for the two types of lesions starting at day 14. Colorimetry, spectroscopy, and histologic
data were also collected, and by day 28 were comparable
for the two types of PIH [27]. The availability of a viable
model will help future researchers better understand the
condition and its management.
In acne, PIH manifests as localized or diffuse brown-togray brown macules at sites of acne lesions and becomes
most apparent after lesional erythema has resolved [6].

Post-inflammatory hyperpigmentation may also appear
violaceous, and that may be a sign of resolving acne where
inflammation is contributing to the violaceous discoloration
more than brownish pigment. In darker skin, erythema may
not be as visible and the only clinical sign of inflammation
may be a more subtle violaceous hue, an important consideration in management decisions. Because acne-associated
pigmentation tends to be long lasting, many patients desire
a management approach that focuses not only on resolving
acne lesions but also on reducing dark spots and improving
overall skin coloration.
The localization of pigment in either the dermis or epidermal layer of the skin affects both the resultant color and
response to treatment [19, 28]. Post-inflammatory hyperpigmentation can be due to overproduction of melanin or
irregular deposition of pigment after cutaneous injury or
inflammation; in addition, the process can involve increased
melanin production by existing melanocytes or by increased
proliferation of active melanocytes [26, 29]. Acne-related
PIH typically involves the epidermis, as melanocytes transfer melanin to surrounding keratinocytes (Fig. 4). Melanin
synthesis takes place within specialized membrane-bound
organelles known as melanosomes, and involves the creation
and exportation of structural proteins from the endoplasmic reticulum and bonding of the proteins with regulatory
glycoproteins that are specific to the melanosome [30]. The

Fig. 4  Schematic of melanocyte transfer of melanin to keratinocytes in the epidermis. BTA benzothiazinyl-alanine, DEJ dermoepidermal junction, DHI 5,6-dihydroxyindole, DHICA 5,6-dihydroxyindole-2-carboxylic acid, DOPA dihydroxyphenylalanine, TRYP tyrosine-related protein
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Fig. 5  Cycle of tyrosinase activation in response to stimuli

complex process of melanin synthesis is regulated by the
sorting and trafficking of protein complexes to the melanosome [26]. Melanocytes reside in the basal epithelial layer
above the dermal-epidermal junction and interact with multiple keratinocytes to transfer melanosomes as needed to
protect the skin [30]. A rise in melanocyte activity can be
stimulated by prostaglandins, cytokines, chemokines, and
additional inflammatory mediators such as reactive oxygen
species [26].
Less frequently, dermal pigment deposition occurs after
adjacent keratinocytes are damaged by inflammation and
release large quantities of melanin [19]. Free pigment is
scavenged by melanophages (a macrophage) in the upper
dermis, contributing to a blue-gray appearance to the skin
[19].
The process of melanogenesis, both in general and in
acne-related PIH, is driven by the enzyme tyrosinase (Fig. 5)
[29]. Perhaps not surprisingly, then, the tyrosinase pathway
is a target for many of the treatments that have been shown
effective in reducing acne-related PIH. Tyrosinase catalyzes
the two major forms of melanins: black/brown eumelanin
and yellow-red pheomelanin [29]. Microphthalmia transcription factor is a “master regulator of melanocyte development, function, and survival” [30] and regulates transcription of tyrosinase and its targets tyrosinase-related proteins
[31, 32]. This may also potentially pose a target for therapeutic intervention.

4 From Bench to Bedside: Managing
Acne‑Associated PIH
4.1 General Measures
Although acne-associated PIH is a common problem, much
of what is known about correcting pigment alteration comes
from melasma studies; going forward, it will be important to
conduct randomized controlled clinical trials in acne-associated PIH to help guide clinicians in therapeutic decisions.
At present, general management strategies start with treating acne as effectively and aggressively as possible without
having the treatment to contribute to additional irritation or
inflammation [33]. However, in part because of the relatively
limited treatment options for PIH, it is important to counsel
patients on methods to prevent further discoloration of skin,
such as regular use of sunscreen, protective clothing, and sun
avoidance; this may be particularly important for those with
darker skin tones, who may not normally practice photoprotection [19]. It is also important to educate patients about not
manipulating or excoriating acne lesions, as this can prolong
pigmentation. Good-quality photos or other imaging can be
helpful to counsel patients about efficacy.

4.2 Therapeutic Approaches
4.2.1 Medical Therapies
As shown in Table 1, medical therapies can correct hypermelanosis by acting at various steps in melanogenesis,

N. Elbuluk et al.
Table 1  Mechanisms of depigmenting agents
Stage of melanin synthesis

Depigmenting agents

Interrupting irritant-induced melanogenesis

Antioxidants: ascorbic acid, alpha-tocopherol, 6-hydroxy-3,4-dihydrocoumarin,
resveratrol, alpha-lipoic acid
Inhibition of tyrosinase activity: arbutin, ascorbic acid, azelaic acid, hydroquinone,
kojic acid, 4-n-butylresorcinol, licorice extracts, topical retinoids
Reduction in tyrosinase production: ceramide, sphingosine-1-phosphate
Increase of tyrosinase degradation: hydroquinone, linoleic acid, linolenic acid, oleic
acid
Niacinamide, lectins, neoglycoproteins, arbutin, soy trypsin inhibitor
Tranexamic acid
Procedures, topical retinoids

Interfering in the tyrosinase pathway

Inhibiting melanosome transfer/maturation
Inhibiting UV plasmin-induced activity in keratinocytes
Increasing epidermal turnover
UV ultraviolet

melanin transfer, and even in the processing or degradation
of melanin [29, 34]. Topical treatments fade excess pigment,
block pigment formation, accelerate skin cell turnover rate,
or work through a combination of these actions. Treatments
that fade excess pigment or block pigment formation include
hydroquinone (HQ), kojic acid, retinoids, and azelaic acid,
while those that increase skin turnover include retinoids.
Topical treatments are generally utilized for epidermal pigmentation, but not for dermal pigmentation because of a
reduced response in the deeper tissue [19].
Hydroquinone, a common treatment for PIH, is a tyrosinase inhibitor that blocks the conversion of melanogenic
precursors. It may also inhibit transcription and expression
at the genetic level, may be cytotoxic to melanocytes, and
may increase the degradation of melanosomes [35]. According to Davis and Callender, HQ monotherapy can reduce
pigmentation, but newer formulations combining HQ with
additional agents, such as retinoids, corticosteroids, glycolic acid, antioxidants, or sunscreens, have shown better
efficacy compared with monotherapy [19]. At concentrations
of 4% and higher, irritation can occur with HQ; adding a
topical corticosteroid reduces this irritation and enhances
depigmenting ability [19]. A triple combination of HQ, a
retinoid, and a corticosteroid (compounded and known as
the Kligman-Willis formula) has shown to be effective but
irritating; more recently, a less-irritating commercial formulation was approved for the treatment of melasma, which
contains 4% HQ, 0.05% tretinoin, and 0.01% fluocinolone
(TriLuma; Galderma, Fort Worth, TX, USA) [19]. In some
settings, concern about steroid-induced acne may limit the
use of triple combination therapy in acne. This formulation,
which is not approved for the treatment of acne-related PIH,
has shown to be both safe and effective for melasma and
photoaging, and successfully used clinically to manage PIH
[19]. More formal study is needed to better define its role
in acne-related PIH. Retinoids increase skin cell turnover,
have anti-inflammatory properties, and can induce apoptosis,
all of which can contribute to skin lightening [19]. Azelaic

acid exerts depigmenting actions by inhibiting tyrosinase
and through selective cytotoxic effects on abnormal melanocytes [19]. Kircik reported positive results with azelaic acid
in a small exploratory study [36]. Most studies of the depigmenting effects of azelaic acid have been in melasma, and
as with other agents, more formal study in acne-related PIH
is warranted. With many medical therapies, it is important
for the clinician to be mindful of the potential of treatments
to cause or exacerbate PIH due to irritation.
4.2.2 Procedures
Adjunctive therapies, such as chemical peels, lasers, and
microneedling, can enhance efficacy. Superficial peels
(including glycolic acid, salicylic acid, and Jessner solution)
have been used safely across skin types for PIH but lasers
are typically reserved for lighter skin types. Microdermabrasion and non-ablative lasers have been used to reduce
pigment alterations, but may not be well suited for patients
who have active acne. Generally, these approaches work in
acne-related PIH by increasing epidermal turnover and promoting re-epithelialization with less pigmented cells [37].
Procedures are accompanied by the risk for creating PIH
complications, with the greatest risk among darker skinned
individuals (phototypes IV–VI). In a study of Asian patients
treated with laser skin resurfacing, Chan et al. reported that
the density and energy of the laser treatment both contribute to the risk of PIH in dark-skinned patients [38]. The
same authors noted that prevention of bulk tissue heating
is also important with laser use, particularly when applied
to small anatomical areas [38–41]. As early as 2013, Alexis
published a review of laser and light-based modalities suitable for darker skin types, noting that while early devices
were associated with a relatively high rate of unacceptable side effects, the technology had evolved significantly
allowing more widespread use in this population. In 2020,
a retrospective chart and photographic review showed two
or more treatments with a low-energy/density, non-ablative,
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fractional 1927-nm wavelength laser improved PIH by a
mean of 43% with no significant side effects, indicating the
benefits that can be achieved with a procedural approach
[40]. Peels and microneedling can also induce pigmentation and should be used with care in people with dark skin
tones [30].

5 Conclusions
Acne-related PIH is a common sequelae of acne vulgaris. Its
pathogenesis and management remain challenging and relatively poorly understood. To improve management and treatment outcomes, it is important to gain a better understanding
of the pathogenesis of acne-associated PIH and to perform
well-designed studies to evaluate the efficacy and safety of
treatments that target different steps of pathogenesis.
Patients with areas of dyschromia particularly on their
face typically feel a significant negative mental and social
impact. Managing acne and acne-related PIH can pose a
challenge for the clinician, owing to the need to adequately
control and treat the process causing the PIH, the length of
time needed for pigmentation to subside, the cost of medications, lack of insurance coverage, and the difficulty of
treating the PIH without bleaching or damaging the surrounding skin. A primary strategy is to prevent the development of PIH during the inflammatory acne phase. With
this and upcoming publications, we hope to increase awareness of the magnitude of the problem and provide guidance
on best treatment practices, including potentially helpful
combination therapy strategies that can treat acne and PIH
concurrently.
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